Clinical Trials Browser

OTHER × Interventional × idelalisib × Clear all

NCT02787369 2026-01-07

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

NCT03890289 2024-11-21

GAUDEALIS

Phase 2 Terminated

5 enrolled 13 charts

Lymphoma, Follicular

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03257722 2024-02-28

PIL

Phase 1/2 Terminated

4 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Phase 2 Completed

65 enrolled 21 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02962401 2023-08-29

RemodelWM3

Phase 2 Completed

Waldenstrom Macroglobulinemia

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03742323 2021-09-05

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02779283 2020-05-26

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01838434 2018-01-30

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 1 Completed

Lymphoma, Mantle-Cell

NCT02439138 2017-01-11

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Phase 2 Terminated

5 enrolled 8 charts

Waldenstrom Macroglobulinemia